Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because patient’s lives depend on it. We imagine a world where cancer is a curable disease.
At Replimune, we live by our values:
United: We Collaborate for a Common Goal.
Audacious: We Are Bold and Innovative.
Dedicated: We Give Our Full Commitment.
Candid: We Are Honest With Each Other.
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, an innovative and collaborative culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity to contribute to the meaningful work we do which could impact the lives of patients.
Join us, as we reshape the future.
Job Summary:
This role will be integral to building out insights and analytics capabilities within Replimune, and a key contributor to the commercial organization in delivering a successful launch for Replimune’s lead asset RP1 in PD-1 failed melanoma, as well as future indications. In addition, this individual will also work on the broader Replimune portfolio, as well as cross-portfolio topics associated with our oncolytic viral platform such as intra-tumoral injection logistics.
This critical role will be expected to work closely with all individuals/teams/functions involved in our asset launches, including senior leaders. This individual will work on key strategic and tactical aspects of successful product commercialization including assessing various partnering and collaboration options and helping to develop and execute the optimal go to market model. Work is expected to span across areas including primary market research, revenue forecasting, competitive intelligence, and data analytics.
This position can be based either in our Woburn/Hybrid office or be a remote role
Key Responsibilities:
Other Responsibilities:
Education:
Required Experience:
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
We are an Equal Opportunity Employer.
#LI-Remote
Software Powered by iCIMS
www.icims.com